Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 4

Conditions

Asthma

Treatments

Drug: Fluticasone propionate/salmeterol

Drug: Fluticasone propionate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00353873

SAM104926

Details and patient eligibility

About

This study will compare two treatment strategies (doubling the dose of inhaled steroids or adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not controlled by inhaled steroid alone at medium dose. The fixed combination SERETIDE 100/50 one inhalation twice daily will be compared to FLIXOTIDE 100 two inhalations twice daily.

Full description

A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100mcg twice daily and fluticasone propionate (FLIXOTIDE™) at a dose of 200mcg twice daily, both delivered via a dry powder inhaler (DISKUS™) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose

Enrollment

506 patients

Sex

All

Ages

4 to 11 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

A documented clinical history of asthma for a period of at least 6 months.
A documented history (within 12 months of Visit 1) of airway reversibility of = 15% based either on Forced expiratory volume (FEV1) or PEF measured pre and post inhalation of 200 mcg salbutamol. (If no documented history of reversibility exists, patients must demonstrate a =15% reversibility at Visit 1).
Receiving an inhaled corticosteroid at a medium dose (beclomethasone dipropionate HydroFluoroAlkane (HFA) non fine particle = 400-500 mcg/day or beclomethasone HFA fine particle = 200mcg/day, or budesonide =400 mcg/day or fluticasone = 200 mcg/day (or fluticasone 250mcg/day if subject is taking a 125mcg MDI rather than the 100mcg Diskus), for at least 3 months prior to Visit 1 and at a stable dose for at least 4 weeks prior to Visit 1.
Able to use the Mini-Wright peak flow meter and subject or parent/guardian had to be able to record the subject's maximum PEF correctly.
Able to perform FEV1 correctly.
Subject's guardian/parent able to complete an eDRC on behalf of the subject. The eDRC should be completed by the guardian/parent.
Able to use a DISKUS™ correctly.
At least one parent(s)/guardian(s) has to give written informed consent to participate in the study.

At the end of the run-in period (Visit 2), subjects must still meet the criteria for entry into the run-in period and also have:

not achieved the criteria for the 'Well-controlled' asthma during two or more of the 4 weeks prior to Visit 2.

Exclusion criteria

Female subjects who have reached menarche.
Received any investigational study medication in the 4 weeks prior to Visit 1.
Experienced a respiratory tract infection in the 4 weeks prior to Visit 1.
Experienced an acute asthma exacerbation requiring emergency room treatment within 4 weeks or hospitalisation within 12 weeks of Visit 1.
Any use of oral/parenteral or depot corticosteroid within 12 weeks of Visit 1.
Any use of long-acting inhaled beta2-agonists or oral beta2-agonists within 4 weeks of Visit 1.
Any use of leukotriene antagonists or theophyllines within 4 weeks of Visit 1.
Any known clinical or laboratory evidence of a serious uncontrolled disease (including serious psychological disorders) which is, in the opinion of the investigator, likely to interfere with the study.
Subjects with a known or suspected hypersensitivity to inhaled corticosteroids, beta2-agonists, or any components of the formulations (e.g. lactose)
A relative of any of the site staff, including the investigator or study co-coordinator.
Has previously been entered into this study.

Subjects will be excluded from participating in the treatment period of the study if the following occurred during the run-in period:

Pre-bronchodilator FEV1 <60% (assuming that measurement was correctly performed).
Any change in asthma medication (excluding use of prophylactic study specific salbutamol for prevention of asthma symptoms due to exercise).
Respiratory tract infection or asthma exacerbation.
Use of oral, parenteral or depot corticosteroids.
Emergency visit due to asthma.
Non-compliance with the completion of the eDRC (i.e. during the 4 week period between visits, non compliance is defined as less than 5 days of completed data within any one week for four weeks - subjects must complete at least 5 days a week for the entire run-in period).